General Surgical Oncology

Within the General and Thoracic Surgical Oncology group of pediatric surgeons, we have specialized surgeons trained in general and thoracic surgical oncology who work side-by-side with our pediatric oncologists to treat a wide variety of solid tumors such as neuroblastoma, ganglioneuroma/ganglioneuroblastoma, liver cancer (hepatoblastoma, HCC, embryonal sarcoma, rhabdoid tumors), tumors of the kidney (Wilms, clear cell sarcoma, Ewing’s sarcoma, congenital mesoblastic nephroma, rhabdoid tumor, and renal cell carcinoma), pancreatic cancer (pseudopapillary tumor, pancreaticoblastoma, and adenocarcinoma) thyroid nodules and cancer, soft tissue sarcoma (rhabdomyosarcoma, Ewing’s sarcoma, alveolar soft parts sarcoma, and synovial sarcoma), neurofibroma and neurofibrosarcoma, gonadal teratomas and cancers, and gastrointestinal cancers such as colon cancer.

This group is also critical in coordinating the multidisciplinary care of our most complex solid tumor patients. 

Our General and Thoracic Surgical Oncologists are prominent members of many of the solid tumor teams within the Texas Children’s Cancer Center including, Neuroblastoma Program, Liver Tumor Program, Rare Tumors Program, Bone Tumor Program, Ewing’s Sarcoma Center, and the Thyroid Cancer Program. Our Fetal Surgery Team cares for the unborn child diagnosed with neck or sacrococcygeal teratomas and coordinates the complex care of these patients with our Head and Neck Surgical Oncologists, Pediatric Anesthesiologists, Pediatric Oncologists, and neonatal intensivists.

Our General and Thoracic Surgical Oncologists collaborate with the adult Division of Surgical Oncology at the Baylor College of Medicine to take care of our adolescent and young adults that present with adult cancers such as gastric cancer, pancreatic cancer, colon cancer, and rectal cancer. Members of the General and Thoracic Surgical Oncology team also lead the Pediatric Surgical Oncology Laboratory which focuses on the biology of neuroblastoma and liver cancer and look for new personalized, targeted therapies for these patients.